"'The 2018 AHA/ACC/Multisociety Guideline on Blood Cholesterol Management,' the '2019 ESC/EAS Guidelines on Dyslipidemia Management', the '2021 ESC Guidelines on cardiovascular Disease Prevention', and the '2021 Canadian Society Guidelines on Dyslipidemia Management' all emphasize the causal role of LDL-C and Apo-B containing lipoproteins in the development of ASCVD'' [44]. Here, APOB is linked to cardiovascular disorder.